GlassScriptPhysician profile
Kabiru O Akere
NPI 1043659444
$1,488.52
in general payments reported to CMS, 2019-2025
17 companies · $644 in 2025
The $644 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $121 · 2023: $301 · 2024: $226 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $366.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.41 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $141.42 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $130.63 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $119.54 | 2023-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $54.28 | 2021-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $51.07 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $42.25 | 2021-2023 | Steglujan, Steglatro |
| Glaxosmithkline, LLC. | $41.99 | 2021-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $35.40 | 2023 | |
| Soleno Therapeutics, INC. | $30.40 | 2025 | Vykat Xr |
| Phadia US INC. | $26.08 | 2025 | Immunocap |
| Abbvie INC. | $24.08 | 2023 | Vraylar |
| Dexcom, INC. | $23.97 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.60 | 2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.93 | 2021 | |
| Genentech USA, INC. | $10.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kabiru Akere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.